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To the Editor: The authors’ comments consist of two parts,
to which we will reply separately.
1) The authors state that next to GDI1, overexpression of
other genes present within the recurrent aberration should
be taken into account as well to explain the MR phenotype
in our families. In particular, the IKBKG gene is a candidate
because mutations have been implicated in IP, often asso-
ciated with neurological abnormalities, and because the
NF-kB pathway has been linked to MR. We completely
agree with a prominent role for the IKBKG gene and its
pathway in neurological disorders and we have taken this
gene seriously into account for a role in the MR phenotype
of our families. However, we identiﬁed a 190 kb duplica-
tion, which overlaps our recurrent aberration, in a female
patient as well as her normal father. This ﬁnding is
described on page 812 of our paper1 and the position of
this polymorphic duplication is illustrated in Figure 2
(horizontal striped bar). This benign copy number variant
includes, among others, IKBKG, which demonstrates that
at least a duplication of this gene does not cause a patholog-
ical condition. Because IKBKG is duplicated in affected
males of our family 4, we excluded it as a candidate gene.
We do mention that we still have to be careful with this
‘‘rejection.’’ We agree, however, that in the sentence onpage 819 ‘‘Moreover, the role of other genes within the aberra-
tion, such as UBL4A and FAM3A, cannot be excluded even
though the apparent 190 kb copy-number polymorphism identi-
ﬁed in a normal male individual seems to exclude a contribution
of a double dosage of both genes in family 4,’’ the IKBKG gene
should have been included as well. Of the remaining genes
in the nonoverlapping aberrant region, we did check brain
expression for all genes. For those with the highest expres-
sion (FLNA, RPL10, ATP6AP1, and GDI1), we checked their
expression levels in patient-derived cell lines. So we did not
focus on GDI1 alone but proposed this gene as the most
likely candidate gene, which is clearly discussed.
2) The authors would have liked us to putmore emphasis
on the recombination events that occur between the two
oppositely oriented LCRs, L1 and L2, and the consequences
these might have on the IKBKG gene. In our study, the aim
was not to describe the NAHR events that occur between
LCR partners (K1 and K2, or L1 and L2). We clearly point
to the occurrence of recombination events (see page 816
‘‘. multiple possible NAHR-driven inversion events that could
have taken place between the subunits of each set’’) that prob-
ably resulted in homogeneity of the entire LCR. Because
IKBKG was not regarded as a candidate dosage-sensitive
gene for the MR phenotype, and because our male patients
as well as their carrier mothers do not show characteristics
features of IP, we did not further investigate the IKBKG010
copy number, which, however, can be deduced from the
oligo-array data (GEO accession numbers GPL9083 and
GSE17813). Finally, in the paper of Fusco et al.,2 the break-
point of the MER67B duplication could have been cloned
because of their correct assumption that theMER67 repeat
could have been involved. Moreover, the breakpoint could
easily be identiﬁed because of a divergent sequence from
the reference sequence resulting from the duplication.
The reason why we were unable to clone their breakpoints
(present somewhere within the LCRs) is because of the
>99% sequence identity, their homogeneity, and because
in our case we don’t have any handle where to look within
the 35-kb-large LCR. Moreover, we always expect to ﬁnd
homogeneic reference sequences,whichprecludedetecting
the breakpoints.
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